國藥一致(000028.SZ):擬斥6000萬元認購國藥中金醫療產業創新投資二期基金
格隆匯7月16日丨國藥一致(000028.SZ)公佈,公司第九屆董事會第一次會議於2021年7月16日召開,審議通過《關於國藥一致認購國藥中金醫療產業創新投資二期基金6000萬元的議案》。
公司作為國藥中金醫療產業創新投資基金(簡稱“產業創新基金”)的有限合夥人將出資人民幣6000萬元投資認購產業創新基金,該基金目標募集規模30億元,國藥中金(上海)私募股權投資管理有限公司(作為產業基金的普通合夥人和管理人。
值得一提的是,公司控股股東國藥控股(01099.HK)及其下屬國藥股份(600511.SH)和中國醫療器械有限公司亦擬分別出資投資認購產業創新基金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.